Free tool
Drug Trial Radar: Dermatology
Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
12
Active, not recruiting, industry sponsors, Dermatology, Phase 3
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed223
12 trials
Showing 1 to 12, recently updated first.
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa (RECHARGE 1)Pivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06799000 · 588 participants · Start Jan 31, 2025 · Primary completion May 17, 2027
Drug: Remibrutinib Dose A; Remibrutinib Dose B and 2 more · For: Hidradenitis Suppurativa
Sites: Phoenix, Arizona; Fort Smith, Arkansas; North Little Rock, Arkansas · 139 sites in all
- A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT06840392 · 565 participants · Start Mar 20, 2025 · Primary completion Jun 3, 2027
Drug: Remibrutinib Dose A; Remibrutinib Dose B and 2 more · For: Hidradenitis Suppurativa
Sites: Birmingham, Alabama; Gilbert, Arizona; Fremont, California · 129 sites in all
- A Study Evaluating BFB759 in Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Bluefin Biomedicine, Inc.Industry
NCT07287644 · 210 participants (planned) · Start Nov 3, 2025 · Primary completion Aug 1, 2027
Drug: BFB759 · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Encino, California; Huntington Beach, California · 64 sites in all
- A Study to Evaluate the Long-Term Safety and Efficacy of Povorcitinib in Participants With Moderate to Severe Hidradenitis SuppurativaPivotal-lookingActive, not recruiting
Incyte CorporationIncyte (INCY)
NCT06212999 · 617 participants · Start Jan 30, 2024 · Primary completion Dec 26, 2026
Drug: Povorcitinib · For: Hidradenitis Suppurativa (HS)
Sites: Phoenix, Arizona; Scottsdale, Arizona; Fort Smith, Arkansas · 165 sites in all
- A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne VulgarisPivotal-lookingActive, not recruiting
Galderma R&DIndustry
NCT07186413 · 561 participants (planned) · Start Sep 23, 2025 · Primary completion Dec 31, 2026
Drug: Trifarotene; Vehicle Cream · For: Acne Vulgaris
Sites: Shanghai, China
- An International, Multicenter, Randomized, Double-Blind, Parallel Group, Vehicle-Controlled, Phase 2/3 Study With Open-Label Extension Evaluating the Efficacy and Safety of Diacerein 1% Ointment for the Treatment of Generalized Epidermolysis Bullosa Simplex (EBS)Pivotal-lookingActive, not recruiting
TWi Biotechnology, Inc.Industry
NCT06073132 · 80 participants (planned) · Start Apr 4, 2024 · Primary completion Jun 10, 2026
Drug: AC-203; Vehicle · For: Generalized Epidermolysis Bullosa Simplex
Sites: Rancho Santa Margarita, California; Stanford, California; Aurora, Colorado · 30 sites in all
- A Study of FCX-007 for Recessive Dystrophic Epidermolysis BullosaPivotal-lookingActive, not recruiting
Castle Creek Biosciences, LLC.Industry
NCT04213261 · 6 participants · Start Jun 9, 2020 · Primary completion Jan 17, 2023
Drug: FCX-007 (dabocemagene autoficel; see below for FCX-007 description) · For: Recessive Dystrophic Epidermolysis Bullosa
Sites: Stanford, California; Aurora, Colorado; Jacksonville, Florida · 5 sites in all
- Safety, Tolerability and Efficacy of QRX003 Lotion in Subjects With Netherton SyndromePivotal-lookingActive, not recruiting
Quoin PharmaceuticalsIndustry
NCT05521438 · 30 participants (planned) · Start Jun 23, 2022 · Primary completion Dec 30, 2025
Drug: QRX003-2% Lotion; QRX003-4% Lotion QAM and 2 more · For: Netherton Syndrome
Sites: San Diego, California; Indianapolis, Indiana; Quincy, Massachusetts · 5 sites in all
- Evaluation of D-Fi for the Treatment of Wounds Due to DEBPivotal-lookingActive, not recruiting
Castle Creek Biosciences, LLC.Industry
NCT06892639 · 32 participants (planned) · Start Mar 27, 2025 · Primary completion Sep 2027
Drug: D-Fi · For: Dystrophic Epidermolysis Bullosa
Sites: Redwood City, California; Santa Margarita, California; Aurora, Colorado · 4 sites in all
- Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III)Pivotal-lookingActive, not recruiting
RHEACELL GmbH & Co. KGIndustry
NCT05838092 · 9 participants · Start Oct 18, 2023 · Primary completion Aug 29, 2025
Drug: allo-APZ2-OTS; Placebo · For: Epidermolysis Bullosa
Sites: Aurora, Colorado; Minneapolis, Minnesota
- Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Epidermolysis Bullosa (Phase III, Cross-over)Pivotal-lookingActive, not recruiting
RHEACELL GmbH & Co. KGIndustry
NCT05464381 · 91 participants · Start Jun 13, 2023 · Primary completion Aug 29, 2025
Drug: allo-APZ2-OTS; Placebo · For: Epidermolysis Bullosa
Sites: Buenos Aires, Argentina; Salzburg, Austria; Santiago, Chile · 16 sites in all
- A Phase 3b Study for the Treatment of Dystrophic Epidermolysis Bullosa (DEB) in New and Previously EB-101 Treated PatientsPivotal-lookingActive, not recruiting
Abeona Therapeutics, IncIndustry
NCT05725018 · 12 participants (planned) · Start Apr 2, 2023 · Primary completion Sep 30, 2025
Drug: EB-101 Surgical application of RDEB wounds · For: Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa; RDEB
Sites: Redwood City, California; Worcester, Massachusetts
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.